Literature DB >> 8123743

LC separation and induced fluorometric detection of rivastatin in blood plasma.

G J Krol1, G W Beck, W Ritter, J T Lettieri.   

Abstract

An LC procedure suitable for quantitative analysis of pg ml-1 concentrations of the HMG-CoA reductase inhibitor rivastatin in blood plasma was developed. The procedure involves an extraction step, chromatography on an ODS column, and fluorometric detection of a post-column photolytic decomposition product that was isolated and identified. The achieved quantitation limit (25 pg ml-1) facilitated analysis of relatively low rivastatin concentrations in plasma that were observed after 100-300 micrograms oral doses of rivastatin. At 25 pg ml-1 concentration the RSD ranged from 3.6 to 13.5% and mean deviation from the nominal value was 8.0%; at 8 ng ml-1 the RSD range was 0.7-3.6% while the mean deviation was -1.8%. The concentrations obtained with the LC procedure were compared to the concentrations obtained with a specific but less sensitive capillary GC method and a radioimmunoassay (RIA) procedure. Concentrations obtained with the HPLC and GC procedures agreed within experimental error; the RIA concentrations were about 30% higher.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8123743     DOI: 10.1016/0731-7085(93)80113-f

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  Tacrolimus/cerivastatin interaction study in liver transplant recipients.

Authors:  W Mück; D A Neal; O Boix; B Voith; R Hasan; G J Alexander
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

2.  Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits.

Authors:  M Shiomi; T Ito
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

Review 3.  Clinical pharmacokinetics of cerivastatin.

Authors:  W Mück
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

4.  Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients.

Authors:  Lutz Renders; Christian S Haas; Jan Liebelt; Martin Oberbarnscheidt; Harald O Schöcklmann; Ulrich Kunzendorf
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

Review 5.  Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions.

Authors:  W Mück
Journal:  Drugs       Date:  1998       Impact factor: 9.546

6.  Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.

Authors:  W Mück; S Unger; K Kawano; G Ahr
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.